Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

NCT01462890 is registered in ClinicalTrials.gov with AGO Study Group as lead sponsor.

NCT NCT01462890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01462890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Lead sponsor
AGO Study Group
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
December 31, 2021
Enrollment
927 (actual)
Sites
131

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube neoplasms, genital diseases, female, ovarian diseases, ovarian neoplasms, peritoneal neoplasms